Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for copd
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
. There is no evidence to use or not to use oral or inhaled corticosteroids outside usual guidelines in COPD patients with COVID19. Antibiotics should be issued only if suspicion of secondary bacterial infection.” Please refer to that document. Please also refer to the NICE Rapid Guideline for the community-based care of patients with chronicobstructivepulmonarydisease (COPD): https://www.nice.org.uk/guidance/ng168 This reiterates the importance of smoking cessation. Strongly encourage patients with COPD who (...) ), there is no routine indication to take rescue antibiotics or additional oral steroids. Do not offer patients with COPD a short course of oral corticosteroids and/or antibiotics to keep at home unless clinically indicated, as set out in the NICE guideline on chronicobstructivepulmonarydisease in over 16s. There should be NO alteration to advanced rescue-pack prescribing or stockpiling inhalers. These seriously compromise the medicines supply chain and equitable access. Best practice at all times
Permalink Copy Page navigation Thorax Actions . 2020 May;75(5):413-421. doi: 10.1136/thoraxjnl-2019-214246. Epub 2020 Mar 30. Supervised Pulmonary Tele-Rehabilitation Versus Pulmonary Rehabilitation in Severe COPD: A Randomised Multicentre Trial , , , , , , , , , , Affiliations Expand Affiliations 1 Respiratory Research Unit, Department of Respiratory Medicine, Hvidovre Hospital, Hvidovre, Denmark email@example.com. 2 Department of Physical and Occupational Therapy, Bispebjerg Hospital (...) and Infectious Diseases, Hillerød Hospital, Hillerød, Denmark. 9 Department of Public Health, University of Copenhagen Faculty of Health Sciences, Copenhagen, Denmark. PMID: 32229541 DOI: Item in Clipboard Supervised Pulmonary Tele-Rehabilitation Versus Pulmonary Rehabilitation in Severe COPD: A Randomised Multicentre Trial Henrik Hansen et al. Thorax . 2020 May . Show details Thorax Actions . 2020 May;75(5):413-421. doi: 10.1136/thoraxjnl-2019-214246. Epub 2020 Mar 30. Authors
, and severity of COPD exacerbations. Thorax . 2002 ; 57 : 759–764 | | | , x 7 Seemungal, T., Harper-Owen, R., Bhowmik, A. et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronicobstructivepulmonarydisease. Am J Respir Crit Care Med . 2001 ; 164 : 1618–1623 | | | , x 8 Sethi, S. Bacteria in exacerbations of chronicobstructivepulmonarydisease: phenomenon or epiphenomenon?. Proc Am Thorac Soc . 2004 ; 1 : 109–114 | | | , x 9 Bafadhel, M., McKenna, S (...) ., Frei, A., Steurer-Stey, C.A. et al. Antibiotics for exacerbations of chronicobstructivepulmonarydisease. Cochrane Database Syst Rev . 2018 ; 10 : CD010257 Limitations of this meta-analysis include no consideration of underlying chronicobstructivepulmonarydisease severity across trials because of poor reporting of lung function and other parameters. Studies were not limited to patients with suspected bacterial infection, who demonstrate the greatest benefit from antibiotics. Thus, the lack
to the clinical effectiveness of the technology. Further information about how the evidence for this briefing was selected is available on request by contacting firstname.lastname@example.org. Published evidence Published evidence Three studies are summarised in this briefing, including 2 randomised controlled trials and 1 observational study. In total, there were 167 people with chronicobstructivepulmonarydisease (COPD) in these studies. The clinical evidence and its strengths and limitations is summarised (...) myCOPD for self-management of chronicobstructivepulmonarydisease myCOPD for self-management of chronicobstructivepulmonarydisease Medtech innovation briefing Published: 1 April 2020 www.nice.org.uk/guidance/mib214 pathways Summary Summary • The technology technology described in this briefing is myCOPD. It helps people with chronicobstructivepulmonarydisease (COPD) to manage their symptoms and reduce the number of healthcare visits they need. It also helps the healthcare professionals
, is a major public health problem that is both preventable and treatable. COPD is characterized by persistent airflowlimitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and lungs to noxious articles or gases. Exacerbations and comorbidities contribute to overall severity in individual patients. Recommendations for the diagnosis and treatment of patients with concurrent COPD and asthma are excluded from this guideline because these patients (...) . In addition to identifying the recently published guidelines that meet the above standards, a literature search was conducted to identify studies relevant to the key questions that are not addressed by the external guidelines. External guidelines eligible for adapting ? 2019 Update of 2017 Global Initiative for ChronicObstructiveLungDisease (GOLD): Global strategy for the diagnosis, management and prevention of COPD ? 2018 KP National Clinical Practice Guideline: ChronicObstructivePulmonaryDisease
. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J. 2020:2000547. 8. Lippi G, Henry BM. Chronicobstructivepulmonarydisease is associated with severe coronavirus disease 2019 (COVID-19). Respiratory Medicine. 2020. DOI: https://doi.org/10.1016/j.rmed.2020.105941 9. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223 (...) distancing in the workplace setting is difficult to implement. Until we fully understand the risks associated with SARS-CoV-2 infection in patients with chroniclungdisease we have placed a high value on limiting exposure based on prior experience with influenza. COPD Management – General Statement In the absence of direct or indirect data that use of current inhaled COPD therapies impacts the severity of SARS-CoV-2 infection, we recommend that maintenance and exacerbation management for COPD
Purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronicobstructivepulmonarydisease (COPD) 1 Public Summary Document Application No. 1530 – Purified human alpha1-proteinase inhibitor for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronicobstructivepulmonarydisease Applicant: National Blood Authority (NBA) Date of MSAC consideration: MSAC 74th Meeting, 22-23 November 2018 Context for decision (...) : MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting National Product List (NPL) blood product listing of purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of A1-PI deficiency, leading to chronicobstructivepulmonarydisease (COPD), was received from the National Blood Authority (NBA) by the Department of Health. 2. MSAC’s advice to the Minister After considering the strength of available
: Targeted lung denervation (TLD) is a bronchoscopic radiofrequency ablation therapy for chronicobstructivepulmonarydisease (COPD), which durably disrupts parasympathetic pulmonary nerves to decrease airway resistance and mucus hypersecretion. Objectives: To determine the safety and impact of TLD on respiratory adverse events. Methods: We conducted a multicenter, randomized, sham bronchoscopy-controlled, double-blind trial in patients with symptomatic (modified Medical Research Council dyspnea scale (...) treated with TLD combined with optimal pharmacotherapy had fewer study-defined respiratory adverse events, including hospitalizations for COPD exacerbation.Clinical trial registered with www.clinicaltrials.gov ( ). Keywords: anticholinergic; bronchoscopy; chronicobstructivepulmonarydisease; nerves; targeted lung denervation. Figures Figure 1. 5 Respiratory adverse events between 3... Figure 1. 13 Respiratory adverse events between 3 and 6.5 months after bronchoscopy for the... Figure 1. Respiratory
COVID-19. Signpost to charities (such as the British Lung Foundation) and support groups (such as NHS Volunteer Responders), and UK government guidance on the mental health and wellbeing aspects of COVID-19. 1.2 Explain to patients with chronicobstructivepulmonarydisease (COPD), and their families and carers, that they are at increased risk of severe illness from COVID-19. 1.3 Be aware that the NICE guideline on chronicobstructivepulmonarydisease in over 16s defines severe airflowobstruction (...) , and they should take appropriate precautions such as: • performing airway clearance techniques in a well-ventilated room • performing airway clearance techniques away from other family members if possible • advising other family members not to enter the room until enough time has passed for aerosols to clear. Find out more from UK government guidance on COVID-19: infection prevention and control. COVID-19 rapid guideline: community-based care of patients with chronicobstructivepulmonarydisease (COPD
, and Blood Institute. COPD national action plan. Washington, D.C.: U.S. Department of Health and Human Services; 2017 [accessed 2018 Jul 6]. Available from: . van Agteren JE, Hnin K, Grosser D, Carson KV, Smith BJ. Bronchoscopic lung volume reduction procedures for chronicobstructivepulmonarydisease. Cochrane Database Syst Rev. 2017;2:CD012158. - - Kaplan RM, Ries AL. Health-related quality of life in emphysema. Proc Am Thorac Soc. 2008;5:561–566. - - Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto (...) similar articles Cited by 1 PubMed Central articles NS Hopkinson. Am J Respir Crit Care Med 200 (11), 1329-1331. 2019. PMID 31560561. References Wheaton AG, Cunningham TJ, Ford ES, Croft JB Centers for Disease Control and Prevention (CDC) Employment and activity limitations among adults with chronicobstructivepulmonarydisease: United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64:289–295. - - U.S. Department of Health and Human Services, National Institutes of Health and National Heart, Lung
Efficacy and safety of inhaled alpha1-antitrypsin in patients with severe alpha1-antitrypsin deficiency and frequent exacerbations of COPD Patients with inherited α1-antitrypsin (AAT) deficiency (ZZ-AATD) and severe chronicobstructivepulmonarydisease (COPD) frequently experience exacerbations. We postulated that inhalation of nebulised AAT would be an effective treatment.We randomly assigned 168 patients to receive twice-daily inhalations of 80 mg AAT solution or placebo for 50 weeks (...) in the AAT-treated group and 2.67 in the placebo group (p=0.31). More patients receiving AAT reported treatment-related treatment-emergent adverse events compared to placebo (57.5% versus 46.9%, respectively) and they were more likely to withdraw from the study. After the first year of the study, when modifications to the handling of the nebuliser were introduced, the rate of safety events in the AAT-treated group dropped to that of the placebo group.We conclude that in AATD patients with severe COPD
Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study Abatacept, a biologic DMARD, was associated with respiratory adverse events in a small subgroup of RA patients with chronicobstructivepulmonarydisease (COPD) in a trial. Whether this potential risk is specific to abatacept or extends to all biologics and targeted synthetic DMARDs (tsDMARDs) is unclear. We assessed the risk of adverse respiratory events (...) associated with biologic and tsDMARDs compared with conventional synthetic DMARDs (csDMARDs) among RA patients with concomitant COPD in a large, real-world cohort.We used a prevalent new-user design to study RA patients with COPD in the US-based MarketScan databases. New users of biologic DMARDs and/or tsDMARDs were matched on time-conditional propensity scores to new users of csDMARDs. Adverse respiratory events were estimated using Cox models comparing current use of biologic/tsDMARDs with csDMARDs.The
of Canada, Richmond Hill, Ontario, Canada; j Institut Universitaire de Cardiologie et de Pneumologie de Qu ebec, Universit e Laval, Qu ebec, Quebec, Canada; k Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; l Respiratory Research Centre, University of Saskatchewan, Saskatoon, Saskatchewan, Canada ABSTRACT In this guideline update, we highlight important and new findings related to pharmacological therapy of chronicobstructivepulmonarydisease (COPD (...) corticost eroïde en inhalation (CSI)/BALA, sauf chez les patients ayant d ej a subi des exac- erbations et dont le nombre d’ eosinophiles de sang p eriph erique est elev e. Il n’y a pas lieu de recourir a la monoth erapie de CSI; lorsqu’ils sont indiqu es, les CSI doivent ^ etre utilis es uniquement KEYWORDS Chronicobstructivepulmonarydisease; COPD; guideline; pharmacotherapy; Canadian Thoracic Society; CTS CONTACT Jean Bourbeau email@example.com Respiratory Epidemiology and Clinical Research
Effect of a Hospital-Initiated Program Combining Transitional Care and Long-term Self-management Support on Outcomes of Patients Hospitalized With ChronicObstructivePulmonaryDisease: A Randomized Clinical Trial. Patients hospitalized for chronicobstructivepulmonarydisease (COPD) exacerbations have high rehospitalization rates and reduced quality of life.To evaluate whether a hospital-initiated program that combined transition and long-term self-management support for patients hospitalized (...) quality of life measured by the St George's Respiratory Questionnaire (SGRQ) at 6 months after discharge (score, 0 [best] to 100 [worst]; 4-point difference is clinically meaningful).Among 240 patients who were randomized (mean [SD] age, 64.9 [9.8] years; 61.7% women), 203 (85%) completed the study. The mean (SD) baseline SGRQ score was 62.3 (18.8) in the intervention group and 63.6 (17.4) in the usual care group. The mean number of COPD-related acute care events per participant at 6 months was 1.40
of Bias Appendix F. Results From Included Studies Appendix G. Results by Severity Appendix H. Adverse Events Appendix I. Inclusion and Exclusion Criteria of Included Studies Appendix J. Sensitivity Analysis Appendix K. Appendix References ES-1 Evidence Summary Background and Objectives Chronicobstructivepulmonarydisease (COPD) is a common respiratorydisease characterized by airflowlimitation and chronicrespiratory symptoms. The global prevalence is estimated to be greater than 10 percent (...) : MeiLan K. Han, M.D., M.S. University of Michigan Ann Arbor, MI Clare Hawkins, M.D. Aspire Health Care Houston, TX Cara Pasquale, M.P.H. COPD Patient Powered Research Network Washington, DC Antonello Punturieri, M.D., Ph.D. National Heart, Lung, and Blood Institute for ChronicObstructivePulmonaryDisease (COPD)/Environment Bethesda, MD Mark Steffen, M.D., M.P.H. Blue Cross and Blue Shield of Minnesota Eagan, MN James J. Stevermer, M.D., M.S.P.H. Department of Family and Community Medicine University
Current and future direct healthcare cost burden of chronicobstructivepulmonarydisease in Alberta, Canada Current and future direct healthcare cost burden of chronicobstructivepulmonarydisease in Alberta, Canada: Canadian Journal of Respiratory, Critical Care, and Sleep Medicine: Vol 0, No 0 | Search in: Journal Revue canadienne des soins respiratoires et critiques et de la médecine du sommeil 25 Views 0 CrossRef citations to date Altmetric Original Research Current and future direct (...) healthcare cost burden of chronicobstructivepulmonarydisease in Alberta, Canada , , , & Published online: 02 Jul 2019 Abstract OBJECTIVES: To examine the resource use and healthcare costs for chronicobstructivepulmonarydisease (COPD) in Alberta, Canada between 2008 and 2016 and model the future costs to 2030. METHODS: Interlinked hospitalization, ambulatory care, practitioner claims and drug databases in Alberta were used to identify COPD healthcare encounters and medications. Canadian Institution
in the medium term (over 5 years ) due to reduced all-cause mortality as well as proof of harm due to a short- term (up to 1 year postoperatively) increase in all-cause mortality. In terms of other outcomes, there were hints of benefit regarding dyspnea (as the only reported symptom of chronicobstructivepulmonarydisease [COPD]) and exacerbations as well as indications of benefit regarding improved exercise capacity and health-related quality of life. When compared to pulmonary rehabilitation (...) ? Dawid Pieper, Institute for Research in Operative Medicine, University Witten/Herdecke, Cologne, Germany ? Erich Stoelben, Lung Hospital Cologne-Merheim, Hospitals of Cologne City, Germany IQWiG thanks the external experts for their collaboration in the project. IQWiG employees ? Ulrike Paschen ? Christoph Mosch ? Stefan Sauerland ? Sibylle Sturtz ? Siw Waffenschmidt Keywords: Pneumonectomy, Bronchoscopy, PulmonaryEmphysema, Benefit Assessment Extract of final report N14-04 Version 1.0 LVR
the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. H18-02 Targeted lung denervation using catheter ablation for chronicobstructivepulmonarydisease – Addendum to Commission H16-01 1 Extract of addendum H18-02 Version 1.0 Targeted lung denervation for COPD 27 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Targeted lung (...) for COPD 27 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - IQWiG employees involved in the addendum: ? Martina Lietz ? Julia Kreis ? Fabian Lotz ? Stefan Sauerland Keywords: Catheter Ablation, PulmonaryDisease – ChronicObstructive, Assessment of Potential, Benefit Assessment Extract of addendum H18-02 Version 1.0 Targeted lung denervation for COPD 27 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Executive summary On 22 March 2018
status”, “geographical region”, “visit”, “baseline” and the interaction terms for “baseline” and “visit” as well as for “treatment group” and “visit”. c: Institute’s calculation. CAT: COPD Assessment Test; COPD: chronicobstructivepulmonarydisease; CI: confidence interval; FF: fluticasone furoate; MD: mean difference; MMRM: mixed-effects model repeated measures; N: number of analysed patients; RCT: randomized controlled trial; SD: standard deviation; SGRQ: St. George`s Respiratory Questionnaire; SE (...) -responders. c: Patients with a reduction in SGRQ total score by = 4 points (a reduction in score indicates improvement). Patients with missing values at baseline or at the date of analysis were rated as non-responders. CAT: COPD Assessment Test; CI: confidence interval; COPD: chronicobstructivepulmonarydisease; FF: fluticasone furoate; n: number of patients with (at least one) event; N: number of analysed patients; RCT: randomized controlled trial; RR: relative risk; SGRQ: St. George`s Respiratory